Identification of prolactin as a novel immunomodulator on the expression of co-stimulatory molecules and cytokine secretions on T and B human lymphocytes.
We investigate the immunomodulator role of prolactin (PRL) on CD4+ and B cell activation from healthy subjects in comparison with hyperprolactinemic patients. Peripheral blood mononuclear cells, CD4+ or B cells, purified, were cultured under different conditions, as follows: with mitogen, without stimulus, with different concentrations of human PRL, with unspecific mitogen plus PRL, or with antibodies against PRL. The results revealed that PRL is produced by lymphocytes, the expression of CD69 and CD154 molecules, and interleukin secretions depend partially on the autocrine PRL, this is supported by the findings that secretions of IL-2, IFNgamma, and co-stimulatory molecule expression were markedly reduced when autocrine PRL was blocked with anti-PRL antibodies. Furthermore, PRL activity was only observed during the first 2 h after activation. In contrast, B cell culture did not show any alteration by adding or blocking PRL in the expression of CD40 and CD86 in both groups: healthy subject and hyperprolactinemic patients.
Laboratorio de Auto-inmunidad, Unidad de Investigación Medica en Inmunología, Hospital de Pediatría, Centro Medico Nacional Siglo XXI, D.F., México.
Karina
K
Chavez-Rueda
Jesús
J
Hérnández
Edgar
E
Zenteno
Alfredo
A
Leaños-Miranda
Ma Victoria
MV
Legorreta-Haquet
Francisco
F
Blanco-Favela
D000328:Adult; D000906:Antibodies / Q000494:pharmacology; D015703:Antigens, CD / Q000378:metabolism*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D051940:B7-2 Antigen; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D023201:CD40 Ligand / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D003208:Concanavalin A / Q000494:pharmacology; D016207:Cytokines / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000276:immunology; D007155:Immunologic Factors / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D037181:Lectins, C-Type; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008562:Membrane Glycoproteins / Q000378:metabolism; D011388:Prolactin / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D000099192:CD69 Antigens
D000906:Antibodies; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D051940:B7-2 Antigen; D023201:CD40 Ligand; D003208:Concanavalin A; D016207:Cytokines; D007155:Immunologic Factors; D007371:Interferon-gamma; D007376:Interleukin-2; D037181:Lectins, C-Type; D008562:Membrane Glycoproteins; D011388:Prolactin; D013755:Tetradecanoylphorbol Acetate; D000099192:CD69 Antigens; C497964:CD86 protein, human